JP5411927B2 - Ccr1アンタゴニストとしてのピラゾール化合物 - Google Patents
Ccr1アンタゴニストとしてのピラゾール化合物 Download PDFInfo
- Publication number
- JP5411927B2 JP5411927B2 JP2011508559A JP2011508559A JP5411927B2 JP 5411927 B2 JP5411927 B2 JP 5411927B2 JP 2011508559 A JP2011508559 A JP 2011508559A JP 2011508559 A JP2011508559 A JP 2011508559A JP 5411927 B2 JP5411927 B2 JP 5411927B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- methyl
- mmol
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005557 antagonist Substances 0.000 title description 10
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 title description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 title description 2
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 115
- 150000001875 compounds Chemical class 0.000 claims description 75
- -1 4-methylpiperidin-1-ylcarbonyl Chemical group 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 8
- 230000006020 chronic inflammation Effects 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 4
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000007787 solid Substances 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 239000012267 brine Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 102000000013 Chemokine CCL3 Human genes 0.000 description 11
- 239000000654 additive Substances 0.000 description 11
- 229910052717 sulfur Chemical group 0.000 description 11
- 108700012434 CCL3 Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000013058 crude material Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 6
- OAPQKGGVDCZENK-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=C(Cl)C=C1 OAPQKGGVDCZENK-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- SABWVDIHVFZKAJ-UHFFFAOYSA-N n-[1-(5-bromopyridin-3-yl)butyl]-1-(4-chlorophenyl)-5-methylpyrazole-4-carboxamide Chemical compound C=1N=CC(Br)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 SABWVDIHVFZKAJ-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- OFMCGCKRVFLZSG-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)butan-1-amine Chemical compound CCCC(N)C1=CN=CC(Br)=C1 OFMCGCKRVFLZSG-UHFFFAOYSA-N 0.000 description 4
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 4
- DUWLIIPTRMQEAP-UHFFFAOYSA-N 2-methylpropane-2-sulfinic acid Chemical compound CC(C)(C)S(O)=O DUWLIIPTRMQEAP-UHFFFAOYSA-N 0.000 description 4
- XLZVOTDMEOGLHV-IBGZPJMESA-N 5-(aminomethyl)-1-(4-chlorophenyl)-n-[(1s)-1-[3-(trifluoromethyl)phenyl]butyl]pyrazole-4-carboxamide Chemical compound N([C@@H](CCC)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(=C1CN)C=NN1C1=CC=C(Cl)C=C1 XLZVOTDMEOGLHV-IBGZPJMESA-N 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- ABUMKYSTSUUJKX-UHFFFAOYSA-N 1-(2-methylsulfonyl-1,3-thiazol-5-yl)propan-1-one Chemical compound CCC(=O)C1=CN=C(S(C)(=O)=O)S1 ABUMKYSTSUUJKX-UHFFFAOYSA-N 0.000 description 3
- AFCMCPJECQNKGW-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-5-methyl-n-[1-(5-methylsulfonylpyridin-3-yl)butyl]pyrazole-4-carboxamide Chemical compound C=1N=CC(S(C)(=O)=O)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(F)C(Cl)=C1 AFCMCPJECQNKGW-UHFFFAOYSA-N 0.000 description 3
- XJSBJYQMNVYEDH-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-5-methylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=C(F)C(Cl)=C1 XJSBJYQMNVYEDH-UHFFFAOYSA-N 0.000 description 3
- XGUHKLARZPWNCN-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(methoxymethyl)pyrazole-4-carboxylic acid Chemical compound COCC1=C(C(O)=O)C=NN1C1=CC=C(Cl)C=C1 XGUHKLARZPWNCN-UHFFFAOYSA-N 0.000 description 3
- QWBKGZXXMNWOQR-QFIPXVFZSA-N 1-(4-chlorophenyl)-5-methyl-n-[(1s)-1-[3-(trifluoromethyl)phenyl]hex-5-enyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)N[C@@H](CCCC=C)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 QWBKGZXXMNWOQR-QFIPXVFZSA-N 0.000 description 3
- HLYYXPDTFLUERX-UHFFFAOYSA-N 3-methyl-pyrazole-4-carboxylic acid Chemical compound CC=1NN=CC=1C(O)=O HLYYXPDTFLUERX-UHFFFAOYSA-N 0.000 description 3
- BKALAWHLNOMLJW-IBGZPJMESA-N 5-(bromomethyl)-1-(4-chlorophenyl)-n-[(1s)-1-[3-(trifluoromethyl)phenyl]butyl]pyrazole-4-carboxamide Chemical compound N([C@@H](CCC)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(=C1CBr)C=NN1C1=CC=C(Cl)C=C1 BKALAWHLNOMLJW-IBGZPJMESA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- IWKZXJHSEPTXRZ-UHFFFAOYSA-N methyl 3-[5-[1-[[1-(4-chlorophenyl)-5-methylpyrazole-4-carbonyl]amino]butyl]pyridin-3-yl]sulfonylpropanoate Chemical compound C=1N=CC(S(=O)(=O)CCC(=O)OC)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 IWKZXJHSEPTXRZ-UHFFFAOYSA-N 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
- FOFSBPLAZXHMPI-JEDNCBNOSA-N (1s)-1-(2-methylsulfonyl-1,3-thiazol-5-yl)propan-1-amine;hydrochloride Chemical compound Cl.CC[C@H](N)C1=CN=C(S(C)(=O)=O)S1 FOFSBPLAZXHMPI-JEDNCBNOSA-N 0.000 description 2
- ODZXRBRYQGYVJY-LURJTMIESA-N (1s)-1-[3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=CC(C(F)(F)F)=C1 ODZXRBRYQGYVJY-LURJTMIESA-N 0.000 description 2
- CRAVHHIABITJNY-FJXQXJEOSA-N (1s)-1-[6-(trifluoromethyl)pyridin-2-yl]butan-1-amine;hydrochloride Chemical compound Cl.CCC[C@H](N)C1=CC=CC(C(F)(F)F)=N1 CRAVHHIABITJNY-FJXQXJEOSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- GZPGJCSZSWJAPE-FQEVSTJZSA-N (5s)-5-[[1-(4-chlorophenyl)-5-methylpyrazole-4-carbonyl]amino]-5-[3-(trifluoromethyl)phenyl]pentanoic acid Chemical compound CC1=C(C(=O)N[C@@H](CCCC(O)=O)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 GZPGJCSZSWJAPE-FQEVSTJZSA-N 0.000 description 2
- DDOWYSIOCWGJQU-JYRVWZFOSA-N (nz)-2-methyl-n-[1-(2-methylsulfonyl-1,3-thiazol-5-yl)propylidene]propane-2-sulfinamide Chemical compound CC(C)(C)S(=O)/N=C(/CC)C1=CN=C(S(C)(=O)=O)S1 DDOWYSIOCWGJQU-JYRVWZFOSA-N 0.000 description 2
- OVDZHDGTFCISGC-UHFFFAOYSA-N 1-(2-bromo-1,3-thiazol-5-yl)propan-1-ol Chemical compound CCC(O)C1=CN=C(Br)S1 OVDZHDGTFCISGC-UHFFFAOYSA-N 0.000 description 2
- JJHJKPZSLFWWKN-UHFFFAOYSA-N 1-(2-bromo-1,3-thiazol-5-yl)propan-1-one Chemical compound CCC(=O)C1=CN=C(Br)S1 JJHJKPZSLFWWKN-UHFFFAOYSA-N 0.000 description 2
- GTFAQMHALMUKOO-IBGZPJMESA-N 1-(4-chlorophenyl)-5-(hydroxymethyl)-n-[(1s)-1-[3-(trifluoromethyl)phenyl]butyl]pyrazole-4-carboxamide Chemical compound N([C@@H](CCC)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(=C1CO)C=NN1C1=CC=C(Cl)C=C1 GTFAQMHALMUKOO-IBGZPJMESA-N 0.000 description 2
- DHCYLFQHKFJVBK-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methyl-n-(1-pyridin-3-ylbutyl)pyrazole-4-carboxamide Chemical compound C=1C=CN=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 DHCYLFQHKFJVBK-UHFFFAOYSA-N 0.000 description 2
- BWARYCWEJPEGJV-SANMLTNESA-N 1-(4-chlorophenyl)-5-methyl-n-[(1s)-5-(4-methylpiperidin-1-yl)-5-oxo-1-[3-(trifluoromethyl)phenyl]pentyl]pyrazole-4-carboxamide Chemical compound C1CC(C)CCN1C(=O)CCC[C@@H](C=1C=C(C=CC=1)C(F)(F)F)NC(=O)C1=C(C)N(C=2C=CC(Cl)=CC=2)N=C1 BWARYCWEJPEGJV-SANMLTNESA-N 0.000 description 2
- GPRDCSKXCQRJCX-SANMLTNESA-N 1-(4-chlorophenyl)-5-methyl-n-[(1s)-5-(pyridin-3-ylamino)-1-[3-(trifluoromethyl)phenyl]pentyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)N[C@@H](CCCCNC=2C=NC=CC=2)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 GPRDCSKXCQRJCX-SANMLTNESA-N 0.000 description 2
- GVQBEWCSBVRCJD-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methyl-n-[1-(2-sulfamoylpyridin-4-yl)butyl]pyrazole-4-carboxamide Chemical compound C=1C=NC(S(N)(=O)=O)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 GVQBEWCSBVRCJD-UHFFFAOYSA-N 0.000 description 2
- KMKFKHSVNQHEJL-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methyl-n-[1-[2-(methylsulfamoyl)pyridin-4-yl]butyl]pyrazole-4-carboxamide Chemical compound C=1C=NC(S(=O)(=O)NC)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 KMKFKHSVNQHEJL-UHFFFAOYSA-N 0.000 description 2
- XWGHBJBEGYELHW-IBGZPJMESA-N 1-(4-chlorophenyl)-n-[(1s)-3-hydroxy-1-[3-(trifluoromethyl)phenyl]propyl]-5-methylpyrazole-4-carboxamide Chemical compound CC1=C(C(=O)N[C@@H](CCO)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 XWGHBJBEGYELHW-IBGZPJMESA-N 0.000 description 2
- VYDNQEUREQXBIS-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[1-[5-(methanesulfonamido)pyridin-3-yl]butyl]-5-methylpyrazole-4-carboxamide Chemical compound C=1N=CC(NS(C)(=O)=O)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 VYDNQEUREQXBIS-UHFFFAOYSA-N 0.000 description 2
- RMUCBIIPUOTBFR-NSHDSACASA-N 1-(5-chloropyridin-2-yl)-5-methyl-n-[(1s)-1-[3-(trifluoromethyl)phenyl]ethyl]pyrazole-4-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=N1 RMUCBIIPUOTBFR-NSHDSACASA-N 0.000 description 2
- BHKICGQTNGRXOL-UHFFFAOYSA-N 1-(5-methylsulfonylpyridin-3-yl)butan-1-amine Chemical compound CCCC(N)C1=CN=CC(S(C)(=O)=O)=C1 BHKICGQTNGRXOL-UHFFFAOYSA-N 0.000 description 2
- DWDXFLOIIYFOAQ-UHFFFAOYSA-N 1-(5-methylsulfonylpyridin-3-yl)butan-1-amine;dihydrochloride Chemical compound Cl.Cl.CCCC(N)C1=CN=CC(S(C)(=O)=O)=C1 DWDXFLOIIYFOAQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DJUWIZUEHXRECB-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carbaldehyde Chemical compound BrC1=NC=C(C=O)S1 DJUWIZUEHXRECB-UHFFFAOYSA-N 0.000 description 2
- FZFVJCWJQGECLH-UHFFFAOYSA-N 3-(3-bromophenyl)-3-[[1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carbonyl]amino]propanoic acid Chemical compound CC1=C(C(=O)NC(CC(O)=O)C=2C=C(Br)C=CC=2)C=NN1C1=CC=C(Cl)C(Cl)=C1 FZFVJCWJQGECLH-UHFFFAOYSA-N 0.000 description 2
- BYQRONZHLCYLKN-UHFFFAOYSA-N 3-(3-bromophenyl)-3-[[1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carbonyl]amino]propanoyl chloride Chemical compound CC1=C(C(=O)NC(CC(Cl)=O)C=2C=C(Br)C=CC=2)C=NN1C1=CC=C(Cl)C(Cl)=C1 BYQRONZHLCYLKN-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- ZKNBQZBRNLAVHS-UHFFFAOYSA-N 3-bromo-5-pyridin-4-ylpyridine Chemical compound BrC1=CN=CC(C=2C=CN=CC=2)=C1 ZKNBQZBRNLAVHS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KEFLQEPOGSJUGQ-IHBJSSOOSA-N 4-[(1s)-1-(tert-butylsulfinylamino)propyl]pyridine-2-carboxamide Chemical compound CC(C)(C)S(=O)N[C@@H](CC)C1=CC=NC(C(N)=O)=C1 KEFLQEPOGSJUGQ-IHBJSSOOSA-N 0.000 description 2
- APADMXVOFQRBNQ-ZETCQYMHSA-N 4-[(1s)-1-aminopropyl]pyridine-2-carboxamide Chemical compound CC[C@H](N)C1=CC=NC(C(N)=O)=C1 APADMXVOFQRBNQ-ZETCQYMHSA-N 0.000 description 2
- XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical compound NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 102000004500 CCR1 Receptors Human genes 0.000 description 2
- 108010017319 CCR1 Receptors Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- SATZVFKUEAMFPB-UHFFFAOYSA-N azanium;sodium;chloride Chemical compound [NH4+].[Na].[Cl-] SATZVFKUEAMFPB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HHYVTIKYZUMDIL-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DDGMTTIQXFKICJ-UHFFFAOYSA-N methyl 1-(4-chlorophenyl)-5-(methoxymethyl)pyrazole-4-carboxylate Chemical compound COCC1=C(C(=O)OC)C=NN1C1=CC=C(Cl)C=C1 DDGMTTIQXFKICJ-UHFFFAOYSA-N 0.000 description 2
- HEZCOBKZSBTIKM-UHFFFAOYSA-N methyl 3-[4-[1-[[1-(4-chlorophenyl)-5-methylpyrazole-4-carbonyl]amino]butyl]pyridin-2-yl]sulfonylpropanoate Chemical compound C=1C=NC(S(=O)(=O)CCC(=O)OC)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 HEZCOBKZSBTIKM-UHFFFAOYSA-N 0.000 description 2
- AYYCGDYJGQKXIO-UHFFFAOYSA-N methyl 3-amino-3-(3-bromophenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=CC(Br)=C1 AYYCGDYJGQKXIO-UHFFFAOYSA-N 0.000 description 2
- QGBPKJFJAVDUNC-UHFFFAOYSA-N methyl 4-methoxy-3-oxobutanoate Chemical compound COCC(=O)CC(=O)OC QGBPKJFJAVDUNC-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- GLJLMDMUSNWHHN-RSXQAXDFSA-N n-[(1s)-1-(2-cyanopyridin-4-yl)propyl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(=O)N[C@@H](CC)C1=CC=NC(C#N)=C1 GLJLMDMUSNWHHN-RSXQAXDFSA-N 0.000 description 2
- WFJQPZFHZNOMJB-UHFFFAOYSA-N n-[(5-bromopyridin-3-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(=O)N=CC1=CN=CC(Br)=C1 WFJQPZFHZNOMJB-UHFFFAOYSA-N 0.000 description 2
- PNWXSXDBIIKBAA-UHFFFAOYSA-N n-[1-(3-bromophenyl)-3-(diethylamino)-3-oxopropyl]-1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carboxamide Chemical compound C=1C=CC(Br)=CC=1C(CC(=O)N(CC)CC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C(Cl)=C1 PNWXSXDBIIKBAA-UHFFFAOYSA-N 0.000 description 2
- ZBFJREMTWBYHFO-NSHDSACASA-N n-butylidene-2-methylpropane-2-sulfinamide Chemical compound CCCC=N[S@@](=O)C(C)(C)C ZBFJREMTWBYHFO-NSHDSACASA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OKIKSXCCVLDWEU-UHFFFAOYSA-N tert-butyl 1-(3-chloro-4-fluorophenyl)-5-methylpyrazole-4-carboxylate Chemical compound CC1=C(C(=O)OC(C)(C)C)C=NN1C1=CC=C(F)C(Cl)=C1 OKIKSXCCVLDWEU-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LHYKNLNRUCYEJS-UHFFFAOYSA-N tert-butyl n-[1-(5-bromopyridin-3-yl)butyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CCC)C1=CN=CC(Br)=C1 LHYKNLNRUCYEJS-UHFFFAOYSA-N 0.000 description 2
- UDNRHGWBOAFHMK-UHFFFAOYSA-N tert-butyl n-[1-(5-methylsulfanylpyridin-3-yl)butyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CCC)C1=CN=CC(SC)=C1 UDNRHGWBOAFHMK-UHFFFAOYSA-N 0.000 description 2
- IBGOTQLQMAMCMB-UHFFFAOYSA-N tert-butyl n-[1-(5-methylsulfonylpyridin-3-yl)butyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CCC)C1=CN=CC(S(C)(=O)=O)=C1 IBGOTQLQMAMCMB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- IGWKEWMLYSVJNC-ZETCQYMHSA-N (1s)-1-(2-bromopyridin-4-yl)propan-1-amine Chemical compound CC[C@H](N)C1=CC=NC(Br)=C1 IGWKEWMLYSVJNC-ZETCQYMHSA-N 0.000 description 1
- SBSTZQZPZYZLKE-JTQLQIEISA-N (1s)-1-(3-bromophenyl)-2-methylpropan-1-amine Chemical compound CC(C)[C@H](N)C1=CC=CC(Br)=C1 SBSTZQZPZYZLKE-JTQLQIEISA-N 0.000 description 1
- AUPBYJHLAMYNNN-NSHDSACASA-N (1s)-1-(3-bromophenyl)-3,3-dimethylbutan-1-amine Chemical compound CC(C)(C)C[C@H](N)C1=CC=CC(Br)=C1 AUPBYJHLAMYNNN-NSHDSACASA-N 0.000 description 1
- CGOUPQXXGWINRE-JTQLQIEISA-N (1s)-1-(3-bromophenyl)but-3-en-1-amine Chemical compound C=CC[C@H](N)C1=CC=CC(Br)=C1 CGOUPQXXGWINRE-JTQLQIEISA-N 0.000 description 1
- ZQDPCRJEZHIKAK-JTQLQIEISA-N (1s)-1-(3-bromophenyl)butan-1-amine Chemical compound CCC[C@H](N)C1=CC=CC(Br)=C1 ZQDPCRJEZHIKAK-JTQLQIEISA-N 0.000 description 1
- LIBZHYLTOAGURM-LURJTMIESA-N (1s)-1-(3-bromophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(Br)=C1 LIBZHYLTOAGURM-LURJTMIESA-N 0.000 description 1
- KNORIHZJMFWEMO-LBPRGKRZSA-N (1s)-1-(3-bromophenyl)hexan-1-amine Chemical compound CCCCC[C@H](N)C1=CC=CC(Br)=C1 KNORIHZJMFWEMO-LBPRGKRZSA-N 0.000 description 1
- CUIAXTURGQALCM-NSHDSACASA-N (1s)-1-(3-bromophenyl)pent-4-en-1-amine Chemical compound C=CCC[C@H](N)C1=CC=CC(Br)=C1 CUIAXTURGQALCM-NSHDSACASA-N 0.000 description 1
- NYTCERYERGQLNU-NSHDSACASA-N (1s)-1-(3-bromophenyl)pentan-1-amine Chemical compound CCCC[C@H](N)C1=CC=CC(Br)=C1 NYTCERYERGQLNU-NSHDSACASA-N 0.000 description 1
- ZVSDXABGZDMDIE-JTQLQIEISA-N (1s)-1-[3-(trifluoromethyl)phenyl]butan-1-amine Chemical compound CCC[C@H](N)C1=CC=CC(C(F)(F)F)=C1 ZVSDXABGZDMDIE-JTQLQIEISA-N 0.000 description 1
- OSRPMKWAUDVBTC-LBPRGKRZSA-N (1s)-1-[3-(trifluoromethyl)phenyl]hex-5-en-1-amine Chemical compound C=CCCC[C@H](N)C1=CC=CC(C(F)(F)F)=C1 OSRPMKWAUDVBTC-LBPRGKRZSA-N 0.000 description 1
- IOKQBZCLCSLBJG-JTQLQIEISA-N (1s)-1-[4-fluoro-3-(trifluoromethyl)phenyl]butan-1-amine Chemical compound CCC[C@H](N)C1=CC=C(F)C(C(F)(F)F)=C1 IOKQBZCLCSLBJG-JTQLQIEISA-N 0.000 description 1
- FYARORXHFRMUIC-YFKPBYRVSA-N (1s)-1-[4-fluoro-3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C(C(F)(F)F)=C1 FYARORXHFRMUIC-YFKPBYRVSA-N 0.000 description 1
- DCPVKNOMQGBFBW-VIFPVBQESA-N (1s)-1-[4-fluoro-3-(trifluoromethyl)phenyl]propan-1-amine Chemical compound CC[C@H](N)C1=CC=C(F)C(C(F)(F)F)=C1 DCPVKNOMQGBFBW-VIFPVBQESA-N 0.000 description 1
- PIOCLGPCMNPZFT-ZETCQYMHSA-N (2s)-1-(3-fluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC(F)=C1 PIOCLGPCMNPZFT-ZETCQYMHSA-N 0.000 description 1
- DWCDDXINAZHRLK-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)hydrazine;hydrochloride Chemical compound [Cl-].[NH3+]NC1=CC=C(F)C(Cl)=C1 DWCDDXINAZHRLK-UHFFFAOYSA-N 0.000 description 1
- YQVZREHUWCCHHX-UHFFFAOYSA-N (4-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Cl)C=C1 YQVZREHUWCCHHX-UHFFFAOYSA-N 0.000 description 1
- LZMCYWOJZWSIJN-UHFFFAOYSA-N 1-(3-bromopyridin-4-yl)butan-1-amine Chemical compound CCCC(N)C1=CC=NC=C1Br LZMCYWOJZWSIJN-UHFFFAOYSA-N 0.000 description 1
- CDZJVORMKFURLG-UHFFFAOYSA-N 1-(4-bromopyridin-3-yl)butan-1-amine Chemical compound CCCC(N)C1=CN=CC=C1Br CDZJVORMKFURLG-UHFFFAOYSA-N 0.000 description 1
- STBSHPQTTMFJIF-FQEVSTJZSA-N 1-(4-chlorophenyl)-5-(methoxymethyl)-n-[(1s)-1-[3-(trifluoromethyl)phenyl]butyl]pyrazole-4-carboxamide Chemical compound N([C@@H](CCC)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(=C1COC)C=NN1C1=CC=C(Cl)C=C1 STBSHPQTTMFJIF-FQEVSTJZSA-N 0.000 description 1
- XHIPWPGZDIGKAA-FQEVSTJZSA-N 1-(4-chlorophenyl)-5-methyl-n-[(1s)-1-[3-(trifluoromethyl)phenyl]but-3-enyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)N[C@@H](CC=C)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 XHIPWPGZDIGKAA-FQEVSTJZSA-N 0.000 description 1
- MDXGMFXMDAJAEL-IBGZPJMESA-N 1-(4-chlorophenyl)-5-methyl-n-[(1s)-3-oxo-1-[3-(trifluoromethyl)phenyl]propyl]pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)N[C@@H](CC=O)C=2C=C(C=CC=2)C(F)(F)F)C=NN1C1=CC=C(Cl)C=C1 MDXGMFXMDAJAEL-IBGZPJMESA-N 0.000 description 1
- CYPBTHPQJZHJCN-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methyl-n-[1-(5-methylsulfonylpyridin-3-yl)butyl]pyrazole-4-carboxamide Chemical compound C=1N=CC(S(C)(=O)=O)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 CYPBTHPQJZHJCN-UHFFFAOYSA-N 0.000 description 1
- QDXMAVVRBPWRSP-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-methyl-n-[1-[6-(oxan-4-ylsulfamoyl)pyridin-3-yl]butyl]pyrazole-4-carboxamide Chemical compound C=1C=C(S(=O)(=O)NC2CCOCC2)N=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 QDXMAVVRBPWRSP-UHFFFAOYSA-N 0.000 description 1
- SSAFJGGLQUSOOG-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[1-[5-(3-hydroxypropylsulfonyl)pyridin-3-yl]butyl]-5-methylpyrazole-4-carboxamide Chemical compound C=1N=CC(S(=O)(=O)CCCO)=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 SSAFJGGLQUSOOG-UHFFFAOYSA-N 0.000 description 1
- UPGPOIOZNZTLTF-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)propan-1-amine Chemical compound CCC(N)C1=CN=CC(Br)=C1 UPGPOIOZNZTLTF-UHFFFAOYSA-N 0.000 description 1
- XPHSVEJIQKWPBT-UHFFFAOYSA-N 1-(5-methylsulfanylpyridin-3-yl)butylcarbamic acid Chemical compound CCCC(NC(O)=O)C1=CC(SC)=CN=C1 XPHSVEJIQKWPBT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 description 1
- AWNVFSSPEXEMAB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]pentanoic acid Chemical compound CCCC(C(O)=O)C1=CC=CC(C(F)(F)F)=C1 AWNVFSSPEXEMAB-UHFFFAOYSA-N 0.000 description 1
- DOWNSQADAFSSAR-UHFFFAOYSA-N 2-bromo-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC(Br)=N1 DOWNSQADAFSSAR-UHFFFAOYSA-N 0.000 description 1
- GTCXYHZNFJRNTE-RFXRWSEHSA-N 2-methyl-n-[(1s)-1-(2-methylsulfonyl-1,3-thiazol-5-yl)propyl]propane-2-sulfinamide Chemical compound CC(C)(C)S(=O)N[C@@H](CC)C1=CN=C(S(C)(=O)=O)S1 GTCXYHZNFJRNTE-RFXRWSEHSA-N 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- RLYAXKJHJUXZOT-UHFFFAOYSA-N 3-amino-3-(3-bromophenyl)propanoic acid Chemical compound OC(=O)CC(N)C1=CC=CC(Br)=C1 RLYAXKJHJUXZOT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- CIMNCXNTYDSTBE-UHFFFAOYSA-N 5-[1-[[1-(4-chlorophenyl)-5-methylpyrazole-4-carbonyl]amino]butyl]pyridine-2-sulfonic acid Chemical compound C=1C=C(S(O)(=O)=O)N=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 CIMNCXNTYDSTBE-UHFFFAOYSA-N 0.000 description 1
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 1
- CXWLXKZIXLOBCC-UHFFFAOYSA-N 5-chloro-2-iodopyridine Chemical compound ClC1=CC=C(I)N=C1 CXWLXKZIXLOBCC-UHFFFAOYSA-N 0.000 description 1
- BZWYSNFWFWLEPL-QMMMGPOBSA-N 5-methyl-n-[(1s)-1-[3-(trifluoromethyl)phenyl]ethyl]-1h-pyrazole-4-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C=1C=NNC=1C BZWYSNFWFWLEPL-QMMMGPOBSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- WWLVIZGKAHLXPY-AWNIVKPZSA-N Bc1cncc(/C=N/S(C(C)(C)C)=O)c1 Chemical compound Bc1cncc(/C=N/S(C(C)(C)C)=O)c1 WWLVIZGKAHLXPY-AWNIVKPZSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- LCZSAPPTYSQGQH-UHFFFAOYSA-N C1COCCC1OS(=O)(=O)O Chemical compound C1COCCC1OS(=O)(=O)O LCZSAPPTYSQGQH-UHFFFAOYSA-N 0.000 description 1
- GDTSZMBKAKSBHW-UHFFFAOYSA-N CC(CC1)CCN1C(CCCC(c1cc(C(F)(F)F)ccc1)NC(C1=C(C)CC(c(cc2)ccc2Cl)=CN=C1)=O)=O Chemical compound CC(CC1)CCN1C(CCCC(c1cc(C(F)(F)F)ccc1)NC(C1=C(C)CC(c(cc2)ccc2Cl)=CN=C1)=O)=O GDTSZMBKAKSBHW-UHFFFAOYSA-N 0.000 description 1
- GMKBLBOQAUDQFT-NNUXYFOWSA-N CC/C=C(\C=N)/S(C)(=O)=O Chemical compound CC/C=C(\C=N)/S(C)(=O)=O GMKBLBOQAUDQFT-NNUXYFOWSA-N 0.000 description 1
- PXPKBDOMBPOWOH-UHFFFAOYSA-N CC1[N-](c(cc2)ccc2Cl)N=CC1C(NC(CCCC(OC)=O)c1cccc(C(F)(F)F)c1)=O Chemical compound CC1[N-](c(cc2)ccc2Cl)N=CC1C(NC(CCCC(OC)=O)c1cccc(C(F)(F)F)c1)=O PXPKBDOMBPOWOH-UHFFFAOYSA-N 0.000 description 1
- ADKYHQQDTKEHAS-UHFFFAOYSA-N CCCC(NC(=O)C1=CNN=C1C)C1=CC(=CN=C1)S(C)(=O)=O Chemical compound CCCC(NC(=O)C1=CNN=C1C)C1=CC(=CN=C1)S(C)(=O)=O ADKYHQQDTKEHAS-UHFFFAOYSA-N 0.000 description 1
- 101150028394 CCR1 gene Proteins 0.000 description 1
- 0 COCC(*(c1ccc(*)cc1)N=C1)=C1C(OC)=O Chemical compound COCC(*(c1ccc(*)cc1)N=C1)=C1C(OC)=O 0.000 description 1
- 238000003650 Calcium Assay Kit Methods 0.000 description 1
- FMJHSZZGLJGNAZ-UHFFFAOYSA-N Cc([n](-c(cc1)ccc1Cl)nc1)c1C(NC)=O Chemical compound Cc([n](-c(cc1)ccc1Cl)nc1)c1C(NC)=O FMJHSZZGLJGNAZ-UHFFFAOYSA-N 0.000 description 1
- LPODYOQSIWYSMO-UHFFFAOYSA-N ClC1=CC=C(C=C1)N1N=CC=C1COC Chemical compound ClC1=CC=C(C=C1)N1N=CC=C1COC LPODYOQSIWYSMO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- FLNKWZNWHZDGRT-UHFFFAOYSA-N azane;dihydrochloride Chemical compound [NH4+].[NH4+].[Cl-].[Cl-] FLNKWZNWHZDGRT-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZOAIGCHJWKDIPJ-UHFFFAOYSA-M caesium acetate Chemical compound [Cs+].CC([O-])=O ZOAIGCHJWKDIPJ-UHFFFAOYSA-M 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BKBMACKZOSMMGT-UHFFFAOYSA-N methanol;toluene Chemical compound OC.CC1=CC=CC=C1 BKBMACKZOSMMGT-UHFFFAOYSA-N 0.000 description 1
- GGICICPHSDATJE-UHFFFAOYSA-N methyl 3-(3-bromophenyl)-3-[[1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carbonyl]amino]propanoate Chemical compound C=1C=CC(Br)=CC=1C(CC(=O)OC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C(Cl)=C1 GGICICPHSDATJE-UHFFFAOYSA-N 0.000 description 1
- WGODSPXAGUEPQJ-UHFFFAOYSA-N methyl 3-[5-[1-[[1-(4-chlorophenyl)-5-methylpyrazole-4-carbonyl]amino]butyl]pyridin-2-yl]sulfonylpropanoate Chemical compound C=1C=C(S(=O)(=O)CCC(=O)OC)N=CC=1C(CCC)NC(=O)C(=C1C)C=NN1C1=CC=C(Cl)C=C1 WGODSPXAGUEPQJ-UHFFFAOYSA-N 0.000 description 1
- ZKUUVVYMPUDTGJ-UHFFFAOYSA-N methyl 5-hydroxy-4-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(O)=C(OC)C=C1[N+]([O-])=O ZKUUVVYMPUDTGJ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- YICFALDKKMHFLT-UHFFFAOYSA-M sodium;3-methoxy-3-oxopropane-1-sulfinate Chemical compound [Na+].COC(=O)CCS([O-])=O YICFALDKKMHFLT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5069308P | 2008-05-06 | 2008-05-06 | |
US61/050,693 | 2008-05-06 | ||
PCT/US2009/042455 WO2009137338A1 (fr) | 2008-05-06 | 2009-05-01 | Composés de pyrazole comme antagonistes de ccr1 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011520806A JP2011520806A (ja) | 2011-07-21 |
JP5411927B2 true JP5411927B2 (ja) | 2014-02-12 |
Family
ID=40801863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011508559A Active JP5411927B2 (ja) | 2008-05-06 | 2009-05-01 | Ccr1アンタゴニストとしてのピラゾール化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8293917B2 (fr) |
EP (1) | EP2297112B1 (fr) |
JP (1) | JP5411927B2 (fr) |
CA (1) | CA2722811C (fr) |
WO (1) | WO2009137338A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134666A1 (fr) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Composés indazole comme antagonistes des récepteurs ccr1 |
CA2722811C (fr) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Composes de pyrazole comme antagonistes de ccr1 |
AU2009296839A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
US8946231B2 (en) * | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
NZ599132A (en) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
EP2493875B1 (fr) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1 |
CN102596908A (zh) * | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
AP3360A (en) * | 2010-01-27 | 2015-07-31 | Boehringer Ingelheim Int | Pyrazole compounds as CRTH2 antagonists |
EP2563787B1 (fr) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1 |
ES2610185T3 (es) * | 2010-09-21 | 2017-04-26 | Eisai R&D Management Co., Ltd. | Composición farmacéutica |
EP2655371B1 (fr) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Composés de pyrazolopipéridine en tant qu'antagonistes de récepteur ccr1 |
WO2012103071A2 (fr) * | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Composés et compositions |
WO2012163848A1 (fr) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques destinés au traitement de la maladie de crohn |
PL2736888T3 (pl) | 2011-07-26 | 2016-04-29 | Sanofi Sa | Pochodne kwasu 3-heteroaroiloamino-propionowego i ich zastosowanie jako środków farmaceutycznych |
CA2852160A1 (fr) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | Nouveaux marqueurs d'infiltrat leucocytaire de rosacee et utilisations de ceux-ci |
EP2871179A4 (fr) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales |
CA2893597C (fr) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Lactames de diazole |
US9169248B2 (en) * | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
JP6787792B2 (ja) | 2014-05-23 | 2020-11-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの処置のための併用治療 |
US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
WO2016202756A1 (fr) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués |
JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 新規な置換グリシン誘導のfxia阻害剤 |
PT3439653T (pt) | 2016-04-07 | 2021-03-25 | Chemocentryx Inc | Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
WO2018167019A1 (fr) * | 2017-03-14 | 2018-09-20 | Boehringer Ingelheim International Gmbh | Composés à base de tosylacétate et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de phgdh |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4999363A (en) | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
CZ289756B6 (cs) | 1991-03-28 | 2002-04-17 | Eisai Co., Ltd. | Heterocyklicko-cyklické aminové deriváty, meziprodukty postupu přípravy těchto sloučenin, farmaceutický prostředek a pouľití uvedených derivátů |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
RU2105005C1 (ru) | 1992-07-03 | 1998-02-20 | Кумиай Кемикал Индастри Ко., Лтд. | Конденсированное гетероциклическое производное, способ его получения и гербицидное средство |
EP0657450B1 (fr) | 1993-06-25 | 1998-09-09 | KumaiI Chemical Industry Co., Ltd. | Derive d'indazolesulfonyluree, son utilisation et intermediaire pour sa production |
CA2207201A1 (fr) | 1994-12-06 | 1996-06-13 | Caroline Henry | Derives de l'azetidine, de la pyrrolidine et de la piperidine utilises comme agonistes des recepteurs 5-ht1 |
GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
JP2000501105A (ja) | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
CA2309175A1 (fr) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Composes therapeutiquement actifs obtenus par remplacement du catechol par un bio-isostere d'indazole dans des inhibiteurs de pde4 |
US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
WO2000076970A2 (fr) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Composes |
DE60022508T2 (de) | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
WO2001000656A2 (fr) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Indazole peptidomimetiques utilises comme antagonistes recepteurs de thrombine |
GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
ES2343787T3 (es) * | 2002-04-11 | 2010-08-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Derivados de amidas heterociclicas de utilizacion como inhibidores de citoquina. |
IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
DE60328690D1 (de) * | 2002-06-12 | 2009-09-17 | Chemocentryx Inc | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen |
TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
EP1664052B1 (fr) | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Heterocycles fusionnes utilises en tant qu'inhibiteurs de la glutamate racemase (muri) |
WO2005061462A2 (fr) * | 2003-12-19 | 2005-07-07 | Neurogen Corporation | Modulateurs de recepteurs neurokinine 3 : derives pyrazoles de diaryle |
AU2006216917A1 (en) | 2005-02-24 | 2006-08-31 | Merck Sharp & Dohme Corp. | Benzazole potentiators of metabotropic glutamate receptors |
CA2609053C (fr) | 2005-05-17 | 2017-04-25 | Sarcode Corporation | Compositions et procedes pour le traitement des troubles oculaires |
NZ564258A (en) | 2005-06-22 | 2011-02-25 | Chemocentryx Inc | Azaindazole compounds and methods of use |
CN102659774A (zh) * | 2005-08-15 | 2012-09-12 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3拮抗剂的哌啶和哌嗪衍生物 |
DK1924561T3 (da) | 2005-09-01 | 2012-12-10 | Lilly Co Eli | 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister |
JP2009513677A (ja) | 2005-10-25 | 2009-04-02 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
EP2044055A4 (fr) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | Composés amidés |
CA2696725A1 (fr) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Derives de pyridine et leurs procedes d'utilisation |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
WO2009134666A1 (fr) | 2008-04-29 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Composés indazole comme antagonistes des récepteurs ccr1 |
CA2722811C (fr) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Composes de pyrazole comme antagonistes de ccr1 |
AU2009296839A1 (en) | 2008-09-26 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Azaindazole compounds as CCR1 receptor antagonists |
NZ599132A (en) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
EP2493875B1 (fr) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1 |
CN102596908A (zh) | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
EP2563787B1 (fr) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1 |
-
2009
- 2009-05-01 CA CA2722811A patent/CA2722811C/fr active Active
- 2009-05-01 US US12/990,248 patent/US8293917B2/en active Active
- 2009-05-01 WO PCT/US2009/042455 patent/WO2009137338A1/fr active Application Filing
- 2009-05-01 JP JP2011508559A patent/JP5411927B2/ja active Active
- 2009-05-01 EP EP09743325A patent/EP2297112B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
US20110230521A1 (en) | 2011-09-22 |
JP2011520806A (ja) | 2011-07-21 |
CA2722811C (fr) | 2016-07-05 |
WO2009137338A1 (fr) | 2009-11-12 |
EP2297112B1 (fr) | 2013-04-03 |
EP2297112A1 (fr) | 2011-03-23 |
CA2722811A1 (fr) | 2009-11-12 |
US8293917B2 (en) | 2012-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5411927B2 (ja) | Ccr1アンタゴニストとしてのピラゾール化合物 | |
EP2285783B1 (fr) | Composés indazole comme antagonistes des récepteurs ccr1 | |
JP5507567B2 (ja) | Ccr1受容体拮抗薬としてのアザインダゾール化合物 | |
JP5807971B2 (ja) | Cxcr3受容体アンタゴニスト | |
JP5542214B2 (ja) | Ccr1受容体アンタゴニストとしての複素環化合物 | |
US8952004B2 (en) | CXCR3 receptor antagonists | |
EP2491028B1 (fr) | Composés indazole et pyrazolopyridine comme antagonistes du récepteur ccr1 | |
JP2007514690A (ja) | ヒスタミンh3アンタゴニストとしてのベンズアゼピン誘導体 | |
CN102317278B (zh) | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己醇拮抗剂 | |
EP2291359A1 (fr) | Dérivés indazoles à substitution phényl ou pyridinyle | |
JP2012514598A (ja) | Cb2受容体を調節するピロリジン化合物 | |
IL198880A (en) | Indazolil's affluent history, their pharmaceutical preparations, their process and their use in the preparation of medications for the treatment of infectious diseases, asthma or copd | |
EA022075B1 (ru) | Азотсодержащие гетероарильные соединения | |
ES2920359T3 (es) | Amidas de pirrolidinas sustituidas II | |
KR100878421B1 (ko) | 5원 환식기를 가지는 환상 디아민 화합물 | |
WO2008098096A1 (fr) | Composés hétérocycliques anti-cytokine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130408 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130930 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131108 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5411927 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |